Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Antti_Vuolanto
|
| gptkbp:country |
gptkb:Finland
|
| gptkbp:developedBy |
CDNF (Cerebral Dopamine Neurotrophic Factor)
xCDNF |
| gptkbp:focusesOn |
gptkb:Parkinson's_disease
neurodegenerative diseases Lymphedema |
| gptkbp:founded |
2008
|
| gptkbp:headquarters_location |
gptkb:Helsinki
|
| https://www.w3.org/2000/01/rdf-schema#label |
Herantis Pharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:languageOfWork |
English
Finnish |
| gptkbp:listedOn |
gptkb:Nasdaq_First_North_Growth_Market_Finland
|
| gptkbp:stockSymbol |
gptkb:HRTIS
|
| gptkbp:website |
https://herantis.com/
|
| gptkbp:bfsParent |
gptkb:BT13
|
| gptkbp:bfsLayer |
6
|